Key Highlights
- Partnership to expand molecular testing across European and UK markets.
- Focus on rapid, in-house cancer diagnosis using NGS liquid biopsy panels.
- Pillar’s oncoRevealTM LBx panels offer high sensitivity with results in less than three days.
- Scalable sequencing for economic value using Illumina NextSeq™.
Source: PR Newswire
Notable Quotes
- “Access to cost-effective, easy-to-use, distributed NGS kits for liquid biopsy testing are critical to support local laboratories in providing clinically actionable results to oncologists and supporting critical treatment decisions for cancer patients globally.” — Dan Harma, Chief Commercial Officer at Pillar Biosciences
- “We are committed to expanding global patient access to biomarker testing, and decentralized NGS solutions are key to this strategy.” — John Longshore, Head of Scientific Affairs, Global Oncology Diagnostics at AstraZeneca
SoHC's Take
This strategic partnership between Pillar Biosciences and AstraZeneca is a significant development in cancer diagnostics, especially in the European and UK markets. The ability to offer rapid and scalable Next Generation Sequencing (NGS) liquid biopsy tumor profiling empowers local laboratories to perform complex cancer diagnostics in-house. By reducing turnaround times from weeks to just a few days, Pillar’s oncoRevealTM LBx panels not only increase efficiency but also enhance clinical decision-making. This collaboration highlights the importance of decentralized testing in improving global access to precision oncology treatments.
Heading
Key Highlights Heidi Chen named Chief Legal Officer at GeneDx, effective November 25, 2024. Brings over 30 years of legal ...
Key Highlights TA Associates completes a strategic growth investment in Vee Healthtek. Vee Healthtek to expand services in healthcare technology ...
Key Highlights Dr. Laura Aguilar named Chief Medical Officer at Diakonos Oncology. DOC1021 dendritic cell vaccine to enter Phase 2 ...
Key Highlights Deb Autor, former FDA Deputy Commissioner, joins Hims & Hers Board of Directors. Janet Stevens, pharmaceutical quality expert, named Global ...
Key Highlights Dr. Gregg A. Pratt joins as Chief Regulatory and Quality Assurance Officer to oversee regulatory and quality functions. Phase ...
Key Highlights Revisto secures $4M in seed funding led by LiveOak Ventures, joined by Eli Lilly and others. AI-driven platform ...
